CytoDyn Inc. announced the appointments of Christopher Recknor, M.D. as Senior Executive VP of Clinical Operations and Nitya Ray, Ph.D. as the Company’s Chief Operating Officer. CytoDyn is realigning its management structure to optimize the BLA resubmission process and to advance clinical development potential. The team of Drs. Ray and Recknor will now hire additional professionals to complement Dr. Srinivasan, Executive Director of CMC Regulatory Affairs, who recently joined CytoDyn from Regeneron. The Company’s central focus remains on completing the BLA resubmission. Dr. Recknor and his clinical development team will manage the clinical and nonclinical activities, while Dr. Ray and his team will manage regulatory submissions, as well as all CMC activities. Dr. Ray has over 30 years of experience in the biotech industry and was one of the original members of the leronlimab (PRO 140) product development team at Progenics.